Compugen Ltd. files foreign-issuer reports that document its clinical-stage cancer immunotherapy business, financial results and material corporate developments. Its Form 6-K filings cover quarterly and annual results, interim consolidated financial statements, management discussion and analysis, Inline XBRL financial data, and corporate updates related to programs such as COM701, COM902, rilvegostomig and GS-0321.
The filing record also documents licensing and royalty arrangements, including amendments to the AstraZeneca rilvegostomig agreement, as well as proxy materials, annual general meeting voting results, board composition and registration-statement incorporation matters under Form F-3. These disclosures frame Compugen's capital resources, collaboration economics, governance actions, clinical-development disclosures and foreign private issuer reporting obligations.
Livnat Savitzky Kinneret reported acquisition or exercise transactions in this Form 4 filing.
Compugen director Livnat Savitzky Kinneret received equity awards on July 29, 2026, including options to purchase 10,000 Ordinary Shares at $2.26 per share expiring July 29, 2036, and 7,500 restricted stock units. Both awards vest 25% on October 1, 2027, with the remainder in 12 equal quarterly installments, subject to continued service. Following the RSU grant, her direct holdings of Ordinary Shares are reported as 20,850, and she also holds the 10,000-share option grant.
Compugen Ltd. director Mathias Hukkelhoven reported equity awards dated July 29, 2026. He received options for 10,000 Ordinary Shares at an exercise price of $2.2600, expiring July 29, 2036, and an RSU award for 7,500 shares. Both awards vest 25% on October 1, 2027, with the remainder in 12 equal quarterly installments, subject to continued service. Following the RSU grant, he directly holds 17,500 Ordinary Shares.
COMPUGEN LTD director Halevy Gilead received new equity awards on July 29, 2026. The grants consist of 7,500 restricted stock units and a share option for 10,000 ordinary shares at an exercise price of $2.26 per share, expiring July 29, 2036. Both the RSUs and the option vest 25% on October 1, 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to continued service. After these awards, Gilead directly holds 18,907 ordinary shares and options for 10,000 shares.
Compugen Ltd director Sanford S. Zweifach received equity-based compensation on July 29, 2026. He was granted 7,500 restricted stock units and a share option for 10,000 ordinary shares at an exercise price of $2.26. Both awards vest 25% on October 1, 2027 and the remainder in 12 equal quarterly installments, subject to continued service. Following these awards he directly holds 20,180 ordinary shares and 10,000 options.
Compugen Chief Medical Officer Michelle Mahler received equity awards on July 29, 2026, consisting of 13,500 restricted stock units and a stock option for 18,000 ordinary shares at an exercise price of $2.26 per share. Both awards vest 25% on September 30, 2027, with the remainder in 12 equal quarterly installments, subject to her continued service. Following the RSU grant, she directly holds 36,625 ordinary shares.
Compugen Ltd senior vice president of business development Zurit Levine exercised options to acquire 1,875 Ordinary Shares at $0.8292 per share and, on the same date, sold 1,875 Ordinary Shares at $2.50 per share in an open-market transaction. The trades were made pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Following these transactions, Levine directly holds 29,375 Ordinary Shares and 3,750 share options with a $0.8292 exercise price expiring on November 9, 2032.
Compugen Ltd. files a shelf registration to offer up to $400,000,000 of securities, including a sales agreement allowing up to $100,000,000 of ordinary shares to be sold under an at-the-market sales agreement with Leerink Partners LLC. The base prospectus covers ordinary shares, debt securities, rights, warrants and units in one or more offerings from time to time after effectiveness. The prospectus notes our ordinary shares trade on Nasdaq and the Tel Aviv Stock Exchange (symbol CGEN) and discloses a closing sale price of $3.03 (Nasdaq) and NIS 8.361 ($2.88 equivalent) on May 14, 2026. The prospectus also summarizes business operations, clinical programs and a March 31, 2026 capitalization table that shows cash and investments and issued ordinary shares.
Compugen Ltd. reported first quarter 2026 results, highlighting steady clinical progress and a solid balance sheet. Revenue was $2.2 million, slightly below the prior year, mainly from recognition of upfront and milestone payments under its Gilead license agreement.
The company recorded a net loss of $7.7 million, or $0.08 per share, similar to the prior-year loss, as increased R&D spending of $6.9 million supported its MAIA-ovarian trial and other programs. General and administrative expenses were stable at $2.3 million.
Compugen ended March 31, 2026 with $134.9 million in cash, cash equivalents, short-term deposits and marketable securities and reported no debt, stating this cash is expected to fund operations into 2029. Management emphasized progress in its immuno-oncology pipeline and noted up to $1 billion in potential milestones plus royalties from partnerships with AstraZeneca and Gilead.
Compugen Ltd SVP of Business Development Zurit Levine exercised options and sold shares in a pre-planned transaction. On April 24, 2026, she exercised 2,000 share options at $1.15 per share and sold 2,000 ordinary shares at $3.20 per share in an open-market sale pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Following these transactions, she directly held 29,375 ordinary shares.